Clinical trials: HPV
Arthritis
Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis
The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called…
- Trial name
- CHASE (NCT00573651)
- Testing
- Blood Draws for Serum Titers
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- University Hospitals Cleveland Medical Center
Human Papilloma Virus
Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators
Invasive cervical cancer incidence and mortality can be dramatically reduced through early detection and treatment, but many women do not complete screening at recommended intervals.
- Trial name
- HPVhometest (NCT03139669)
- Testing
- Viba collection brush
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Human Papillomavirus Infection, Self Sampling
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc. developed a safe and comfortable vaginal self-sampling device "Hygeia Touch Self Sampling Kit for Women" to self-collect the vaginal discharge sample for high-risk Human Papillomavirus (hrHPV) detection.
- Conditions
- Human Papillomavirus Infection, Self Sampling, Vaginal Discharge
- Trial name
- NCT04472377
- Testing
- Self sampling kit for collecting discharge from vaginal fornix
- Where
- 3 sites in Taiwan
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Hygeia Touch Inc.
GARDASIL Vaccination
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus…
- Trial name
- NCT01343485
- Testing
- Computer reminder system
- Where
- 9 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Planned Parenthood Federation of America
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Infections, Papillomavirus
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
This is a multicenter study in which women are planned to receive either the HPV vaccine or control. Study participation will last approximately 72 months and involves a total of thirteen or fourteen scheduled visits.
- Trial name
- NCT00779766
- Testing
- HPV GSK 580299 vaccine
- Where
- 4 sites in China
- Volunteers
- 6,081 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Vaccines
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial
HPV vaccine coverage among adolescents in the US is suboptimal. This is particularly true among traditionally underserved adolescents. Few parent-targeted interventions have focused on the parental decision-making process.
- Trial name
- NCT02535845
- Testing
- Project Voice, HPV Informational Video
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar high-grade squamous intraepithelial lesion (HSIL) [vulval…
- Conditions
- Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2
- Trial name
- NCT03180684
- Testing
- VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
- Where
- 15 sites in United States
- Volunteers
- 33 people
- Sponsor
- Inovio Pharmaceuticals
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design.
- Conditions
- HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT03260023
- Testing
- TG4001, Avelumab
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 143 people
- Sponsor
- Transgene
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00849381
- Testing
- GSK580299, GSK Biological's HPV vaccine
- Where
- 9 sites in Brazil, Taiwan and 1 more
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus, Human Immunodeficiency Virus
Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention
The purpose of this research study is to determine the best way to increase screening for cervical cancer, colorectal cancer, HIV, and Hepatitis C among under screened Hispanic, Haitian and African-American individuals in…
- Conditions
- Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
- Trial name
- NCT02970136
- Testing
- OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick
- Where
- United States
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- University of Miami
Cervical Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer. PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well…
- Conditions
- Cervical Cancer, Nonneoplastic Condition, Precancerous Condition
- Trial name
- NCT00667563
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, DNA analysis, polymerase chain reaction
- Where
- India
- Volunteers
- 150 people
- Sponsor
- AIDS Malignancy Consortium
Head and Neck Squamous Cell Cancer
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck…
- Trial name
- NCT02163057
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Inovio Pharmaceuticals
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
The goal of this clinical research study is to learn if utomilumab, when given with ISA101b, is able to shrink or slow the growth of tumors in patients with incurable HPV+ oropharyngeal squamous cell carcinoma.
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Trial name
- NCT03258008
- Testing
- Utomilumab, ISA101b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Infections, Meningococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults
The purpose of this study is to evaluate safety and immunogenicity of GSK Biologicals' meningococcal vaccine GSK134612 (MenACWY-TT) co-administered with Cervarix as compared to MenACWY-TT and Cervarix administered alone and the…
- Trial name
- NCT01755689
- Testing
- Meningococcal vaccine GSK134612, Cervarix®, Boostrix®
- Where
- 3 sites in Dominican Republic, Estonia and 1 more
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
Women sometimes develop cancer in an area called the cervix, which is the opening to the uterus, or womb. Women who have HIV are more likely to get this kind of cancer than women who do not have HIV.
- Trial name
- NCT01315353
- Testing
- Cervical Cryotherapy, Loop Electrosurgical Excision Procedure (LEEP)
- Where
- 13 sites in Botswana, Haiti and 5 more
- Volunteers
- 467 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Infections, Papillomavirus
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years.
- Trial name
- NCT00996125
- Testing
- CervarixTM, Control
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV…
- Trial name
- NCT00937950
- Testing
- Gynaecological follow-up
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 2,022 people
- Sponsor
- GlaxoSmithKline
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago